Novel Analgesics for the Treatment of Bone Cancer Pain

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$109,305.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA110524-01
Agency Tracking Number:
CA110524
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ST. CHARLES PHARMACEUTICALS
ST. CHARLES PHARMACEUTICALS, PO BOX 850616, NEW ORLEANS, LA, 70185
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ANTHONY VACCARINO
(504) 280-6771
AVACCARI@STCHARLESPHARMA.COM
Business Contact:
KENNETH NARDUCY
() -
KNARDUCY@MSN.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Pain is the most prevalent symptom in cancer patients, and bone metastasis is one of the most common sources of cancer-related pain. In the 3-step guidelines established by the World Health Organization (WHO) non-opioid analgesics (acetaminophen and NSAIDs) are the first step against cancer pain. In step 2, when pain relief is not achieved with non-opioid medications, synergistic opioid/non-opioid combinations (e.g., codeine + acetaminophen) are used. Thus, acetaminophen is a heavily used efficacious treatment for bone cancer-related pain. However, it has been recognized that even at therapeutic doses acetaminophen causes liver toxicity. Cancer patients are exposed to a multitude of chemotherapeutics that tax liver function to the limit, and thus are particularly susceptible to acetaminophen-induced liver toxicity. Therefore, an acetaminophen-like analgesic that does not deplete glutathione stores would increase the ability to treat cancer-related pain with Step 1 and Step 2 medications, and fill an important void in the options available to cancer patients. We are currently exploring a series of new and proprietary derivatives of acetaminophen, in which the lead compound (SCP-1) has good oral efficacy that is synergistic with opioids, and appears to overcome the hepatotoxic shortcomings of acetaminophen. Under this Phase I SBIR project, we will determine the feasibility of using this unique compound as stage 1 and stage 2 treatments of bone cancer pain.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government